Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719121 | 0.92 | ESR1 (0.35) | GRM2ESR1ESR2PIK3CDPIK3CA | |
| SCHEMBL6734897 | 0.89 | SCN5A (0.36) | GRM2SCN5AESR1ESR2PTGS2 | |
| SCHEMBL6741262 | 0.89 | PTGS2 (0.37) | GRM2SCN5AESR1ESR2PTGS2 | |
| SCHEMBL6719155 | 0.88 | ESR1 (0.39) | ESR1ESR2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6726563 | 0.88 | TGFBR1 (0.43) | ESR1ESR2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6729964 | 0.87 | GRM2 (0.37) | GRM2SCN5APIK3CDPIK3CAPIK3CB | |
| SCHEMBL6718891 | 0.87 | PTGS2 (0.43) | ESR1ESR2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6723527 | 0.86 | KIF11 (0.40) | ESR1ESR2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6721645 | 0.86 | ESR1 (0.40) | SCN5AESR1ESR2PIK3CDPIK3CA | |
| SCHEMBL6718684 | 0.85 | ESR1 (0.37) | ESR1ESR2PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | GRM2 893/4885SCN5A 4251/4885ESR1 1770/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | GRM2 814/4885SCN5A 4246/4885ESR1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.